Literature DB >> 2566190

Neuropeptides in Alzheimer's disease: a postmortem study.

C B Nemeroff1, J S Kizer, G P Reynolds, G Bissette.   

Abstract

The concentration of 5 neuropeptides, neurotensin (NT), somatostatin (SRIF), corticotropin-releasing factor (CRF), bombesin and thyrotropin-releasing hormone (TRH) was measured in 3 cerebrocortical areas and several subcortical regions in post-mortem brains obtained from patients with histologically verified Alzheimer's disease and from controls without neurological or psychiatric disorders using sensitive and specific radioimmunoassay procedures. In Alzheimer's disease, reductions in the concentration of SRIF and CRF were observed in frontal and temporal cortex. In addition, in Alzheimer's disease, SRIF was also reduced in concentration in the hypothalamus, whereas CRF concentrations were reduced in the caudate nucleus. Neurotensin was reduced in concentration in the amygdala in Alzheimer's disease. No alterations in TRH or bombesin/gastrin-releasing peptide were found. These findings provide further evidence for the pathological involvement of certain neuropeptide-containing neurons in Alzheimer's disease.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2566190     DOI: 10.1016/0167-0115(89)90254-1

Source DB:  PubMed          Journal:  Regul Pept        ISSN: 0167-0115


  10 in total

1.  NADPH-diaphorase-positive cell populations in the human amygdala and temporal cortex: neuroanatomy, peptidergic characteristics and aspects of aging and Alzheimer's disease.

Authors:  J W Unger; W Lange
Journal:  Acta Neuropathol       Date:  1992       Impact factor: 17.088

2.  Longitudinal brain corticotropin releasing factor and somatostatin in a transgenic mouse (TG2576) model of Alzheimer's disease.

Authors:  Jennifer Horgan; Jose Javier Miguel-Hidalgo; Martha Thrasher; Garth Bissette
Journal:  J Alzheimers Dis       Date:  2007-09       Impact factor: 4.472

3.  Neuropeptide gene expression in brain is differentially regulated by midbrain dopamine neurons.

Authors:  N Lindefors; S Brené; M Herrera-Marschitz; H Persson
Journal:  Exp Brain Res       Date:  1990       Impact factor: 1.972

4.  Impact of CRFR1 Ablation on Amyloid-β Production and Accumulation in a Mouse Model of Alzheimer's Disease.

Authors:  Shannon N Campbell; Cheng Zhang; Allyson D Roe; Nickey Lee; Kathleen U Lao; Louise Monte; Michael C Donohue; Robert A Rissman
Journal:  J Alzheimers Dis       Date:  2015       Impact factor: 4.472

Review 5.  The CRF System as a Therapeutic Target for Neuropsychiatric Disorders.

Authors:  Jeff Sanders; Charles Nemeroff
Journal:  Trends Pharmacol Sci       Date:  2016-10-04       Impact factor: 14.819

6.  Somatostatin-like immunoreactivity, its molecular forms and monoaminergic metabolites in aged and demented patients with Parkinson's disease--effect of L-Dopa.

Authors:  M Strittmatter; G F Hamann; D Strubel; H Cramer; K Schimrigk
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

Review 7.  Metabolic and Non-Cognitive Manifestations of Alzheimer's Disease: The Hypothalamus as Both Culprit and Target of Pathology.

Authors:  Makoto Ishii; Costantino Iadecola
Journal:  Cell Metab       Date:  2015-09-10       Impact factor: 27.287

8.  Corticotropin-releasing factor receptor-1 antagonism mitigates beta amyloid pathology and cognitive and synaptic deficits in a mouse model of Alzheimer's disease.

Authors:  Cheng Zhang; Ching-Chang Kuo; Setareh H Moghadam; Louise Monte; Shannon N Campbell; Kenner C Rice; Paul E Sawchenko; Eliezer Masliah; Robert A Rissman
Journal:  Alzheimers Dement       Date:  2015-11-07       Impact factor: 21.566

Review 9.  Corticotropin releasing factor-binding protein (CRF-BP) as a potential new therapeutic target in Alzheimer's disease and stress disorders.

Authors:  Dorien Vandael; Natalia V Gounko
Journal:  Transl Psychiatry       Date:  2019-10-22       Impact factor: 6.222

10.  Dissecting the role of sortilin receptor signaling in neurodegeneration induced by NGF deprivation.

Authors:  Simona Capsoni; Gianluca Amato; Domenico Vignone; Chiara Criscuolo; Anders Nykjaer; Antonino Cattaneo
Journal:  Biochem Biophys Res Commun       Date:  2013-01-11       Impact factor: 3.575

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.